Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IMUXthis companyImmunic, Inc.	$7.99	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
ACETAdicet Bio, Inc.	$3.15	-0.5×	0.36×	0×	-0.31×	-8.6%	0.0%	0.0%	0.0%	-73.4%	-70.2%	-167.1%	0.09×	0.22×	-3,392.06×	7.47×	0.0%	1	-6.93	3	B-
ACRVAcrivon Therapeutics, Inc. Common Stock	$1.67	-1.19×	0.82×	0×	-0.71×	-40.7%	0.0%	0.0%	0.0%	-69.2%	-73.0%	-70.4%	0.02×	0.51×	0×	7.69×	0.0%	1	-2.78	3	B-
BMEABiomea Fusion, Inc.	$0.60	-1.05×	2.19×	0×	-0.17×	48.4%	0.0%	0.0%	0.0%	-209.1%	-166.2%	-108.7%	0.05×	0.9×	0×	5.23×	0.0%	0	-18.95	2	C+
CBUSCibus, Inc.	$1.21	-0.63×	3.65×	21.88×	-3.72×	-625.8%	-62.8%	-1853.9%	-3492.3%	-582.2%	-23.2%	-64.3%	12.28×	-2.84×	-1.9×	0.72×	0.0%	3	-4.45	1	D+
LITSLite Strategy, Inc.	$1.03	-0.45×	0.77×	0×	-2.13×	-83.7%	0.0%	0.0%	0.0%	-170.9%	-29.5%	-28.6%	0×	0.47×	0×	5.74×	0.0%	1	0.13	2	C
Peer median	—	-0.63×	0.82×	0×	-0.71×	-40.7%	0.0%	0.0%	0.0%	-170.9%	-70.2%	-70.4%	0.05×	0.47×	0×	5.74×	0.0%	1	-4.45	2	—